医药合作年度盛会，80+医药领袖、700+业内同仁与您共聚杭州，开启药企创新出海新篇章！

本次大会第二日特设“MNC+Pharma”和“Global Biotech”两个主题路演专场，超20场路演席位火热征集中，将邀请在某个领域获得突破性进展并在寻求合作、投资机会的企业参与。

此次路演旨在加强企业间的交流与合作，将是企业展现优势项目、寻找合作伙伴的绝佳舞台。

席位紧张，报名从速！

更多赞助、演讲等合作细节欢迎详询洽谈！ 

On the second day of the conference, there will be two roadshow sessions, "MNC+Pharma" and "Global Biotech", and over 20 roadshow sessions will be held to invite companies that have made breakthroughs in a certain field and are looking for cooperation and investment opportunities.

The roadshow aims to strengthen the communication and cooperation between enterprises, and will be an excellent stage for enterprises to showcase their advantageous projects and find partners.

For more details on sponsorship, speeches and other cooperation, please contact us to discuss.

【招商火热进行中，扫码立即咨询】

Aili Li

T：(86 21) 6095 7201

M：138 4991 9680

E：[email protected]

首席执行官，执行董事/

CEO & Executive Director

基石药业/CStone Pharmaceuticals

临床医学专家、科学家，拥有海外大型跨国药企、科研院所等机构逾25年的学术科研及生物制药研发的资深经验，涵盖从药物发现, 转化医学到临床开发阶段。发表文章/会议报告50余篇，拥有专利9项；

现任基石药业首席执行官以及执行董事，全面负责基石各项业务发展以及策略制定；六年时间里带领基石药业成功上市四款创新药，分别为泰吉华®（阿伐替尼），普吉华®（普拉替尼），择捷美®（舒格利单抗），拓舒沃®（艾伏尼布）；曾任百济神州高级副总裁及临床开发负责人；组建百济神州临床团队，并领导4个肿瘤药物从一期到关键试验阶段的临床开发工作，包括已获批上市的中国首个自主研发的抗PD-1替雷利珠单抗，BTK抑制剂泽布替尼和PARP抑制剂帕米帕利；曾任美国科文斯肿瘤医学总监；曾任辉瑞肿瘤生物标记物资深首席科学家；曾任Tularik/Amgen公司研究科学家; 领导超过十个肿瘤项目的研究与开发；拥有美国德州西南医学院博士学位，师从诺贝尔奖获得者Mike Brown博士和Joseph Goldstein博士；哈佛大学博士后，师从Stuart Schreiber博士；此前在南京医科大学和湖北医学院咸宁分院取得医学学位。

首席执行官/CEO

华领医药/Hua Medicine (Shanghai) Ltd.

陈力博士，华领医药创始人、董事长、首席执行官兼首席科学官，建立了全球第一家实现血糖传感器葡萄糖激酶激活剂(GKA)临床开发的公司，实现了糖尿病新药多格列艾汀全球首创、中国首发。在他的带领下，华领医药成功完成了两项53周III期注册临床研究，并于2021年获NMPA受理NDA申请。在此期间，成功完成2亿美元融资，并与拜耳和国药集团建立了商业化合作伙伴关系。

陈力博士1992年毕业于爱荷华州立大学，获博士学位，同年加入罗氏美国研发中心，从一名药物化学资深研究员成长为高通量技术部主任，2004年回国建立罗氏中国研发中心，任首席科学官和董事。陈力博士是80件授权发明专利和212件发明专利申请的发明人，并发表近70篇科学论文（截止2022年8月）。

Dr. Li Chen, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer, leads Hua Medicine a clinical stage biotech company whose mission is to bring disease modifying diabetes medicines to patients in China and worldwide. Hua Medicine leverages global resources to develop a first-in-class GKA dorzagliatin for diabetes. Under his leadership, Hua Medicine successfully completed registration trial, filed China NDA and demonstrated diabetes remission induced by dorzagliatin. During this period, Hua Medicine raised 200M USD and established commercialization partnership with Bayer and Sionpharm for dorzagliatin.

Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 80 granted patents, 212 patent applications and an author with about 70 publications (Until August 2022).

副总经理，全球研发总裁/VP, President of Global R&D

恒瑞医药/Hengrui Pharmaceuticals

2017年2日加入信达，目前主要负责国内BD，主导完成了葆元、劲方、来凯，参与和支持了赛诺菲、礼来、罗氏、亚盛、Coherus、MD Anderson、Etana合作交易。

Joined Innovent in Feb, 2017, and is currently responsible for China BD, and has led recent Innovent transactions with AnHeart, GenFleet, and Laekna, and has also supported the SVP of Business Development for in establishing several of Innovent’s existing partnerships with Sanofi, Lilly, Roche, Ascentage, Coherus, MD Anderson, Etana etc.

业务发展副总裁/BD VP

先声药业/Simcere Pharmaceutical

陈晨 (Michael) 博士，现担任江苏先声药业副总裁，主要负责领导公司业务发展和联盟管理中国团队的工作。

在加入先声之前，陈博士曾担任中山康方BD副总裁，和德国默克公司医药研发外部创新亚太区负责。在默克工作期间，陈博士是默克亚洲和中国研发中心的领导成员之一，针对自身研发管线，协助团队开展亚太地区的协同工作，并管理亚太地区以建立起来的研发创新外部合作。

归国前，陈博士先后在英国埃塞克斯大学获得细胞和分子生物学学士学位、英国诺丁汉大学获得癌症免疫治疗硕士学位、英国伦敦帝国理工大学获得生物化学博士学位。在加入默克之前，他曾在伦敦大学学院从事博士后研究，之后在英国生物技术公司 Spirogen（后被阿斯利康集团旗下全球生物制药分公司 MedImmune 收购） 领导研究项目，归国后加入药明生物和睿智化学开展商务拓展及投资工作。

联席首席商务发展官/Co-Chief Business Officer

复星医药/Fosun Pharmaceutical 

袁宁博士现任上海复星医药集团副总裁兼联席首席商务发展官，负责复星医药的产品和技术引进及对外合作。袁宁博士在医药行业有着近20年的研发、营销、并购和BD工作经验，在复星医药工作期间帮助公司达成了多项具有影响力的产品合作。

As the Vice President & Co-Chief Business Officer, Dr. Ning Yuan leads licensing and partnering of pharmaceutical products and technologies in Shanghai Fosun Pharma. Dr. Yuan has been engaged in R&D, marketing, M&A and business development in the industry for nearly 20 years. During his working in Fosun Pharma, Dr. Yuan has made quite a few influential deals for the company.

亚太区合作负责人、副总裁/Head of Roche Pharma Partnering Asia

罗氏制药/Roche

Harm-Jan Borgeld, Head of Roche Pharma Partnering Asia is responsible for the negotiations of innovative, Asia sourced, deals to transform R&D strategic wants into global research and development plans to improve Roche’s external innovation portfolio with first in-class and best in-class compounds. Harm-Jan is based in Shanghai and is a member of the Leadership Team of Roche Pharma Partnering.

Having grown up in the Netherlands, had various careers and roles in the army, academia and pharmaceutical industry. He graduated in 1993 from Wageningen University, his passion was biochemistry and business administration.

He received 6 honors and awards, including 1st prize winner in McKinsey 2001 Business Plan Competition, Netherlands, and an award for Excellent Leadership as Lieutenant in the Dutch Army.

He conducted his PhD research at the Faculty of Medicine, Nagoya University in Nagoya, Japan in 1995 before finishing his Postdoctoral fellowship of Research Institute from Institute of Applied BioTechnology. His focus area was mitochondrial gene therapy, where he developed a novel approach to selectively remove mutated DNA from the mitochondria and creating a possible pathway for treatment options for patients. In 2001 he moved to the Netherlands for his MBA at Rotterdam School of Management, in 2002 to the US to study for his MBA at the Haas Business School. He graduated in 2003.

In 2003, he joined Kyorin Pharmaceuticals, in Germany, as Head BD where he negotiated 3 deals and created 2 business plans for the region Europe.

He spent most of his career at Merck Healthcare KGaA, over 15 years in various positions, he started in 2005 as Senior Licensing Manager in Business Development. In 2008 he became Global Project Team Leader, where he led the clinical development of an immune-oncology antibody. From 2010 he was the Vice President, Head Global Alliance Management. His group oversaw 110-120 global alliances in Research, Development, Commercial and 15-20 regional alliances in Latin America.

董事长兼首席执行官/

Chairman and CEO

烨辉医药/BioNova Pharmaceuticals

华烨博士是烨辉医药科技有限公司（BioNova Pharmaceuticals）的创始人和CEO。基于填补未满足临床医学需求为出发点，建立国际领先的医药研发企业为目标，华博士和创业团队于2018年10月创立了烨辉，借力于实力卓著的资本支持，烨辉医药布局创新靶点的新药自主研发、同时也将海外优质在研阶段的创新小分子靶向及ADC药物引进中国进行临床开发及新药注册。凭借精干的研发团队、尖端的生物科技和充足的研发资金，烨辉医药致力于为中国和全球的患者提供临床急需的创新药物。

华博士拥有20多年的新药临床开发和全球新药注册的经验。在创立烨辉医药前，华博士曾担任和记黄埔医药资深副总裁，负责临床与注册部门。

Ye Hua, MD, MPH is the founder and CEO of BioNova Pharmaceuticals, a start-up biopharmaceutical company that is dedicated to the development and commercialization of innovative medicines for the treatment of cancers and other diseases with high unmet medical needs. The company focuses on building a robust pipeline through internal R&D programs, collaborations with global partners, and selective license and acquisitions. With a highly capable management team, cutting edge biotechnology, and substantial funding, BioNova is committed to delivering high quality innovative medicines to the patients in China and globally.

Dr. Hua is a senior drug developer who has 20+ years’ global clinical development and new drug registration experience with track records in the pharmaceutical industry. Prior to building up BioNova, Dr. Hua was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchmed, a leading R&D biotech company headquartered in Shanghai China.

首席业务拓展官/Chief Business Development Officer

赛生医药/Sciclone Pharmaceuticals

朱凌宇博士在国际制药行业已经工作了20年的时间，他先后在跨国制药企业（美国辉瑞公司和强生公司）和本土创新制药企业（贝达药业）主持战略合作及对外投资业务。到目前为止，朱博士完成了28项总价值超过30亿美元的战略合作及对外投资项目，这其中就包括了2014 年 10 月贝达药业对美国 Xcovery公司2千万美金的战略投资并收购了恩沙替尼的中国权益，以及 2013 年5月贝达药业与美国安进公司在中国建立合资企业推动安进公司的帕妥木单抗在中国的注册报批和市场化。

Dr. Zhu has more than 20 years of experience in the pharmaceutical industry and worked with both global pharmaceutical companies (Pfizer and JNJ) and Chinese pharmaceutical company. He has done 28 strategic transactions (total value > US$3 billion) including the 2 recent landmark deals in China, the Joint Venture agreement between Amgen and Betta Pharma to commercialize Amgen’s Vectibix® (panitumumab) in China for colorectal cancer patients in May 2013, and the US$20 million strategic investment in Xcovery by Betta Pharma and acquired the China right of Ensartinib in October 2014.

首席战略及财务官/Chief Strategy and Financial Officer

腾盛博药/Brii Biosciences

李博士是香港上市公司腾盛博药（HK2137）的首席战略及财务官，在投资银行、商务拓展与授权、法律以及生物医药研究领域有超过十年的卓越经验。加入腾盛博药前，李博士曾在拓臻生物担任首席财务官。李博士还曾任高盛医疗投资银行部执行董事和跨国制药公司默沙东亚太创新中心总监。李博士还曾先后在全球知名律所达维律师事务所和瑞格律师事务所工作，为客户提供资本市场和并购交易方面的法律咨询。在职业生涯更早阶段，李博士还曾在索克生物科学研究所从事博士后研究。

李安康博士从芝加哥大学获得法学博士学位，贝勒医学院获得生物医药博士学位，新加坡国立大学获得生物科学硕士学位，在复旦大学获得生物化学学士学位。他还是特许金融分析师持证人。

Dr. Li is Chief Financial Officer at Brii Biosciences. He has more than 10 years of experience in investment banking, business development, legal transaction and biomedical research. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in MSD Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that Dr. Li worked at international law firms, Davis Polk and Ropes & Gray, advising clients on M&A and investment transactions. Earlier in his career, he conducted postdoctoral biomedical research as Salk Institute in Dr. Ronald Evans’s lab.

Ankang Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).

管理合伙人/Partner

三一创投/Trinity Innovation (Beijing) Investment Management 

三一创新（北京）投资管理公司是一家专注在生物医药创新领域的投资机构。创办三一创新（北京）投资管理公司之前，尹正博士曾任国投创新投资管理公司董事总经理，专注生物医药行业股权投资，主要投资项目有迪哲、亚盛、康希诺、瑞博、信达、博瑞等。尹正博士在生物医药领域积累了多层次、丰富的行业经验，在国外工作期间先后服务于生物技术公司与大型跨国制药企业Novartis，负责新药创制与项目管理；回国后在国内著名高等学府从事与生物医药相关的教学、科研、管理和咨询等工作，曾任南开大学药学院院长、药物化学生物学国家重点实验室副主任、清华大学基础分子科学中心执行主任等职务；受聘为多个国家级行业与科技专业委员会的成员。尹正博士还曾担任普华永道投资与并购咨询业务总监，开展生物医药行业投资与并购咨询业务。

尹正博士拥有南开大学学士学位和硕士学位，新加坡国立大学理学博士学位。

Trinity Innovation (Beijing) Investment Management Co., Ltd is an investment institution focusing on the field of biomedical innovation. Before starting the company, Dr. Yin Served as the managing director of SDIC Innovation Investment Management Co., Ltd., responsible for equity investment in the pharmaceutical and healthcare sector, such as Dizal, Ribo, Ascentage, CanSino, Bright-gene, Ribo and EpimAb. Dr. Yin Worked in both biotech and global multinational pharmaceutical companies Novartis,  responsible for innovative drug discovery and project management; Previous positions include Dean of the School of Pharmacy of Nankai University, Deputy Director of the State Key Laboratory of Medicinal Chemical Biology, and Executive Director of the Center for Basic Molecular Science of Tsinghua University. He has been employed as a member of several national industry and science and technology professional committees. Dr. Yin Zheng also served as the PWC Investment and M&A of Consulting Director, and carried out investment and M &A consulting business in the Biomedical Industry.

Bachelor and Master degree from Nankai University; Ph.D. of Science, National University of Singapore.

董事总经理/Managing Director

晨兴创投/MorningSide

沈女士于2010年加入晨兴创投，主要负责生物医药的投资管理，目前担任十余家生物医药/医疗服务创业公司的董事。沈女士具有18年生物医药/医疗健康领域的工作经验，深刻理解医疗健康尤其生物医药企业的机会和挑战。加入晨兴创投之前，沈女士在两家生物医药企业担任新药注册和商务拓展负责人。沈女士是复旦大学工商管理硕士，西安交通大学生物化学与分子生物学硕士。

Lily joined Morningside in 2010 and serves as board directors in more than ten Morningside portfolio companies. She has worked in life science industry for 18 years with rich experience in investment management and new drug R&D management in China. Lily received her master degree in M.B.A from Fudan University and Biochemistry and Molecular Biology from Xi’an Jiaotong University.

联合创始人, 董事长兼首席执行官/

Co-Founder, Chairman, CEO

昂阔医药/OnCusp Therapeutics

袁斌博士是美国哥伦比亚大学分子生物学博士，康奈尔大学商学院MBA和南京大学生物化学学士。他是创业者和医药业务拓展，市场营销和新产品研发战略的资深专家，曾经在不同阶段为包括可瑞达（Keytruda），格列卫(Glivec) 在内的13个国际癌症药的成功做出过突出贡献。在创立OnCusp 之前，他担任基石药业首席战略官和首席商务官，作为最早高管之一，参与领导了从公司起步，上市到商业化转型的全过程，建立和管理过包括业务拓展、公共关系、研发项目管理及商业化团队等十余个职能部门，完成了与辉瑞，拜耳，Blueprint，Agios, EQRx 等近十项国际合作。在2016年11 月之前，他在美国工作学习了22年，曾任美国默沙东癌症类药业务拓展全球主管和执行总监，诺华癌症事业部产品生命周期管理全球主管和商务执行总监，卫材全球市场部癌症新产品战略高级经理， 赛默飞世尔产品经理等职务，成功领导或参与了四十余个并购、转让及临床研发合作的业务拓展项目，作为项目组核心成员制订过5个癌症药的早期研发战略，负责过重磅癌症药Glivec和Afinitor在专利过期前的策略制定，并参加了肺癌药Zykadia的全球上市。

Dr. Bing Yuan is an entrepreneur and a seasoned business executive in business development and licensing (BD&L), marketing and new product strategy. He has made significant contributions to 13 approved global oncology drugs at various stages of product life cycle, including blockbusters such as Keytruda and Glivec. Before founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals.  As a senior executive from the beginning, he helped to build the company from startup to successful IPO and then becoming a commercial stage biopharma. At CStone, he established and managed over 10 departments, such as BD&L, public relations, R&D project management and commercial organization.  He successfully reached close to 10 strategic partnerships with Pfizer, Bayer, Blueprint, Agios, EQRx, etc. Before joining CStone in November 2016, he spent 22 years in the USA. He was Executive Director and Global Lead of Oncology BD&L at Merck (MSD), Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, Global Oncology Marketing Lead at Eisai, and Product Manager at Thermo-Fisher. He successfully led or contributed to over 40 M&A, licensing and Keytruda clinical collaboration deals. As a core member of the global project team (GPT), he played a key role in designing development strategy for 5 oncology drugs. He used to lead Glivec and Afinitor brand life cycle strategy and participated in global launch of Zykadia in ALK+ lung cancer. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University. 

董事长/CEO

艾美斐生物/Immunophage Biotech 

范国煌博士是医学专家，药理学专家，国家自然科学奖获得者，中国科学院“百人计划”学者，同济大学兼职教授，博士生导师。范国煌博士曾担任世界制药巨头葛兰素史克研发中心管理新药研发团队负责人，开展针对重大疾病的药物研发，完成多种新药的临床前研究，所领导的多项新药开发项目进入临床试验。范国煌博士拥有25年恶性肿瘤和神经退行性病变等重大疾病的药理学研究经验，在国际重要期刊上发表50余篇研究论文，获得10余项发明专利。曾先后被评为国家自然科学奖（二等奖）、中华医学科技奖（一等奖）、上海市科技进步奖（一等奖）、美国NIH特别神经科学奖、2021年南京科技顶尖专家等荣誉。

Senior Vice President, Business Development

信达生物/Innovent Biologics 

Mr. Blake Salisbury is responsible for BD activities at Innovent, where he has led the partnering efforts for cross-border deals with Sanofi, Lilly, Roche, Coherus, Alector, Hanmi, MD Anderson, and others. He received his MBA from Thunderbird Graduate School of Global Management. He has 30 years of experience in pharma/biotech, primarily in business development (23 years), but also in sales, marketing, and pricing. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types.

首席执行官/CEO

红云生物/Red Cloud Bio

廖迈菁博士在创新药物和生物科技领域有着多年广泛和丰富的经验。在加入红云生物之前，廖博士作为和铂医药控股有限公司（02142.hk）联合创始人，曾担任和铂医药执行董事、首席商务官和首席商业官。他还先后在美国强生所属 Centocor 公司和西安杨森制药公司的市场部、战略市场部及业务发展部担任要职， 参与和领导过多项免疫及肿瘤创新药物的上市、市场营销及对外合作。廖迈菁博士在康奈尔大学 Johnson 管理学院获得 MBA 学位，在北卡罗来纳大学教堂山分校获得生物化学与生物物理学博士学位，并在麻省理工学院 Whitehead 生命医学研究所 Robert Weinberg 博士实验室从事博士后研究。

Before joining RedCloud Bio, Dr. Mai-Jing Liao was a co-founder of HBM Holdings Ltd. (02142.hk), in the roles of Executive Director of the Board, Chief Commercial Officer and Chief Business Officer. He also served in multiple roles in marketing, strategic marketing and business development of Johnson & Johnson’s Centocor and Xi’an Janssen, where he was responsible for the launch and marketing of many innovative drugs for immunological diseases and cancers.

Dr. Liao received his MBA from Johnson School at Cornell University and his Ph.D. from The University of North Carolina at Chapel Hill. Dr. Liao was a postdoctoral fellow in Dr. Robert Weinberg’s laboratory at Whitehead Institute for Biomedical Research, MIT.

首席商务官兼首席运营官/CBO and COO

斯微生物/StemiRNA Therapeutics

张继国先生现任斯微生物首席商务官，在加入斯微生物之前，张继国先生先后在药明生物担任疫苗业务副总裁，药明康德担任战略副总裁。张继国先生还曾在GSK疫苗总部担任新兴市场副总裁兼中国管理委员会成员。他的职业生涯从销售开始，曾在辉瑞中国和西安杨森任职，先后担任产品经理，新业务发展负责人，战略市场总监，在战略、业务发展、营销管理等方面积累了丰富经验。张继国先生也是虹博基因的创始人，曾以优异的成绩毕业于北京大学医学部以及北京大学国家发展研究院。

Jeffrey Zhang is the Chief Commercial Officer of Microbiology. Prior to joining SMC, Jeffrey Zhang served as Vice President of Vaccine Business at WuXi Biologics and Vice President of Strategy at WuXi AppTec. Jeffrey Zhang also served as Vice President of Emerging Markets and member of the China Management Committee at GSK Vaccine Headquarters. He started his career in sales, working for Pfizer China and Xi'an Janssen, where he served as Product Manager, Head of New Business Development, and Director of Strategic Marketing, gaining extensive experience in strategy, business development, and marketing management. Jeffrey Zhang is also the founder of Hongbo Genetics and graduated with honors from Peking University School of Medicine and Peking University National Development Institute.

Translated with www.DeepL.com/Translator (free version)

管理咨询业务大中华区负责人/Consulting Services Leader

科睿唯安/Clarivate Analytics

江雪博士现任科睿唯安（Clarivate）大中华区管理咨询业务（含生命科学与医疗健康）负责人。

他有超过13年生命科学与医疗健康领域行业经验，包括10年多的管理咨询和行业分析经验，以及2年工业研发和技术转移上的经验。

加入科睿唯安之前，江雪博士曾就职于药明康德上海总部，负责建立差异化的行业分析和咨询能力。他也曾就职于欧睿国际北美分部，为《财富》500强企业、领先新创公司、政府部门和投资机构等客户提供管理咨询和行业研究服务，并接受过美联社、Financial Post和CTV News等媒体采访，阐释行业观点。

他拥有美国Rutgers罗格斯大学（与UMDNJ新泽西医科和牙科大学联合项目）生物医学工程博士学位、上海交通大学学士学位（Top5%）以及多项发明专利。他还致力于消除贫困、科技普及和战胜疾病等方面的公益和慈善事业。

Dr. Xue Jiang is the Consulting Service Leader (including Life   Sciences and Healthcare) of Greater China at Clarivate Consulting.

He has 13+ years of industry experience in the life sciences and   healthcare sector, including more than 10 years of experience in management   consulting and industry analysis, and 2 years in industrial R&D and   technology transfer.

Prior to joining Clarivate, Dr. Jiang worked at WuXi AppTec   headquarters in Shanghai, where he was responsible for building   differentiated industry analysis and consulting capabilities. He has also   worked for Euromonitor International in North America, where he has provided   management consulting and industry research services to Fortune 500   companies, leading startups, government agencies and investment firms, and   has been interviewed by media outlets such as the Associated Press, Financial   Post and CTV News to share industry insight and perspectives.

He holds a Ph.D. in biomedical engineering from Rutgers University (a joint program with UMDNJ, University of Medical & Dental of New Jersey), a bachelor's degree from Shanghai Jiao Tong University (Top5%), and several utility patents. He is also committed to public welfare and philanthropic causes such as poverty eradication, promotion of science & technology, and the fight against disease.

财务咨询合伙人/Financial Advisory Partner

德勤/Deloitte

罗天健先生是德勤中国并购交易咨询合伙人以及德勤中国生命科学与医疗行业财务咨询核心成员。他在审计、海外资本市场、尽职调查及财务咨询服务等领域有15年的专业经验，专长于兼并收购交易相关的财务尽职调查、收购价值建议、并购谈判支持等领域，并已为超过150宗国内并购案和60宗跨境并购案提供建议。罗先生曾在英国伦敦审计、资本市场和并购交易团队工作8年，在欧洲完成近50件企业上市和并购交易案。

董事总经理，全球合伙人/Managing Director and Partner

波士顿咨询/Boston Consulting Group

胡奇聪博士是波士顿咨询公司（BCG）的董事总经理，全球合伙人，BCG医疗保健专项的核心领导。

胡博士他在生物医药、生命科学等多个领域拥有近15年的学术研究、丰富的行业和项目经验。相关项目经验包括：帮助多家知名国内外医药和生命科学企业制定中长期发展战略；帮助多家企业识别各疾病治疗领域的国内外项目机会；帮助多家生物药企业规划中长期战略；实现研发组织管控体系设计和转型；支持多家企业上市新产品，包括第一个肿瘤免疫产品上市工作等。

胡博士是斯坦福大学生物医学博士，曾在《科学》杂志上发表过一作文章， 被Faculty of 1000选为当年排名第二生物医学文章。

Dr. Qicong Hu is a Managing Director and   Partner of Boston Consulting Group (BCG), and a core leader of BCG Greater   China Health Care practice area.

Dr. Hu has 15- year experience in health   care. He served leading clients on high impact programs, with deep expertise   in the space of biopharma (R&D, product launch, biologics/biosimilars,   marketing access, life science, BD/CD and emerging therapies.

His major project experience includes: Led   strategy, portfolio planning/upgrading and early-stage pipeline screening   through AI and machine learning for a leading local client; redesign of   R&D organizations to improve productivity, including org re-structure,   decision-making processes, operational efficiency uplift, and KPIs &   incentive redesign; Strategy design and execution with deep understanding   reimbursement pathway and Payer dynamics; Served top life science players on   China strategies including market landscaping, GTM and digital strategies;   Served local and MNC client to scout for innovation/targets and support in   deal sourcing, cDD and deal transactions, etc.

Dr. Hu earned a Ph.D. in Biomedical Sciences from Stanford. He published 8 articles in world renowned journals, including a first-author paper published on the journal Science.

首席投资官/Chief Investment Officer

先声药业/Simcere Pharmaceutical 

周高波，先声药业首席投资官，负责公司创新药投资和合作业务的拓展、新投资平台建设以及战略规划与实践。

加入先声药业之前，周高波先生在麦肯锡公司担任全球董事合伙人和大中华区医疗咨询联席负责人，拥有十五年医疗行业管理咨询经验，致力于为领先的制药、生物科技、医疗器械、生命科学投资公司提供战略和管理咨询服务，深入探索中国 医改和创新环境下的企业战略、创新商业模式、数字化转型、投资合作，并组建了行业内最大的医疗领域管理咨询团队。此前，他在人类基因组科学公司(HGSI)从事抗体和融合蛋白药物的研发工作。

周高波先生拥有杜克大学商学院的工商管理硕士学位，马里兰大学生物化学硕士学位和复旦大学的遗传学本科学位。

Mr. Zhou Gaobo is the Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in charge of the company's innovative drug investment and business development, establishment of new investment platforms, and investment strategy planning and practice. 

Prior to joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharma­ceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in the context of China's Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development. 

Mr. Gaobo Zhou holds an MBA from Duke University, a Master's Degree in Biochemistry from the University of Maryland, and a Bachelor's Degree in Genetics from Fudan University. 

商务拓展负责人/Head of Business Development

和誉生物/Abbisko Therapeutics

姜华博士，和誉医药商务拓展负责人。姜博士具有十余年的药物研发、商务合作及团队管理经验，对于创新药项目的各个阶段都有较深刻的认识。在加入和誉之前，姜博士曾先后于勃林格殷格翰（BI）和雅培药品业务（Abbott）的外部创新部门担任管理岗位，负责创新与对外合作业务。加入BI之前，姜博士还曾在诺华生物医学研究中心工作近十年，担任研发项目负责人，带领团队从事创新药物的早期研发工作。姜华博士目前领导和誉医药的商务拓展团队，负责全球商务运作和业务拓展，包括产品和技术的引进、合作开发等。

Hua worked in pharmaceutical industry for more than 13 years after his Ph.D. in Biology training from CAS and academic research work in SJTU. Before joining Abbisko, Hua worked for Abbott pharmaceutical division as Director of External Innovation, responsible for asset scouting and licensing. Before that Hua worked in Beohringer Ingelheim as AD of Global External Innovation based in Shanghai. More than external innovation, Hua worked almost 10 years (2009-2019) in China Novartis Institute for BioMedical Research (NIBR) as scientist and then project leader, gained hands-on experience for early stage drug discovery.

总经理/CEO

华奥泰生物/Huaota Biopharm

朱向阳博士，“国家引才计划专家”，“浙江省领军人才”，是生物制药研发和工艺开发方面的专家，在单抗筛选和鉴定，双靶点抗体的工程改造，细胞株的建立，工艺开发, 技术转移, 中试厂房的设计和建设等领域拥有丰富经验。朱向阳博士目前是上海华奥泰生物股份有限公司总经理，负责公司的全球生物制药研发。领导华奥泰生物共计获得17个新药临床批件，推进11个项目至不同临床开发阶段，完成40个新药专利全球申请，领导并建立了一支400多人的创新团队、完成了1000L中试生产平台，GMP质量体系、15000平米的大分子制药商业化生产平台的搭建和完善。

朱向阳博士曾长期在勃林格殷格翰（BI）的不同领域和地点工作（美国，德国，中国），领导和参与了20多个单抗或双靶点抗体项目的研究，是Risankizumab早期项目负责人和发明人，该产品目前已由Abbvie上市。朱向阳博士在伊利诺伊大学获得免疫学博士学位。

Dr. Zhu is an expert in antibody drug discovery and process development with more than 18 years of industrial experience. He has extensive experience in antibody drug discovery, process development, and manufacture facility construction. Dr. Zhu is the CEO for both Huaota Biopharm and Huabo Biopharm (members of Huahai Pharm), leads its global biotherapeutic research. Prior to join Huahai, he worked at Boehringer Ingelheim for more than 8 years in different function areas at multiple locations ( Ridgefield, USA; Biberach, Germany; and Shanghai, China). He led and engaged in over 20 global BI biological research projects including current clinic Phase I-III projects and market products; Dr. Zhu obtained his PhD in microbiology and immunology from the University of Illinois at Chicago .

总经理助理/Assistant General Manager

君实生物/Junshi Biosciences

俞文冰先生现为君实生物总经理助理，分管投融资，是公司香港上市、科创板上市和再融资等项目组主要成员之一，目前主要负责公司投资人沟通，公司的股权融资，以及对外投资等业务。在加入君实生物之前，俞先生拥有超过12年金融行业工作经验，曾经工作于中海基金，长江证券，广发证券和光大证券，曾多次获得新财富、水晶球等分析师评选的第一第二名，曾多次获得深交所、中国证券业协会等评选的优秀研究课题。

Mr. Yu is the assistant general manager of Junshi   Biosciences, in charge of investment and financing. He is a core member of   company’s financing projects like HKEX listing, SSE STAR Market listing and   refinancing. Currently, he is mainly responsible for the company's investor   communication, equity financing, and external Investment related businesses.   Before joining Junshi, Mr. Yu has more than 12 years of experience in the   financial industry. He previously held positions in Zhonghai Fund, Changjiang   Securities, GF Securities and Everbright Securities. He also won Crystal Ball   Sell-Side Analysts Awards and the Best Analyst of New Fortune for many times,   with many excellent research projects selected by the SZSE and the SAC.

首席商务官/CBO

康宁杰瑞/Alphamab Oncology

韩净先生目前供职于康宁杰瑞担任首席商务官职位，主要负责公司商业化运营，上市前临床协调部工作以及外包产品（石药先声）商业化合作。在此之前，韩净先生担任嘉和生物高级副总裁职位，负责组建营销团队及上市前各项商业化工作。在担任上海君实生物副总经理期间，建立营销部搭建团队至550人，制定以大医学概念为前提的市场销售策略，2018年在比竞争对手少一半人员的情况下完成7.74亿销售（10个月），费用比仅48%（信达76%，百济2020年上市第一年90%以上）；开展肺肝食管淋巴瘤等癌肿ISS项目80余项，部分如肝内胆管癌（PD-1+仑伐+Gemox，40%，上海中山医院樊嘉周俭）ORR达90%，后正式立项三期三臂临床，二期数据列入2021年CSCO胆管癌治疗指南。作为临床医生出生的韩净先生也曾在罗氏制药、拜耳医药、 阿斯利康、勃林格殷格翰、默沙东等大型跨国药企均有过从业经验。

合伙人/Partner

鼎豐生科资本/Pivotal bioVenture Partners China

钱晶女士于2018年成为鼎豐生科資本合伙人。在此之前，她任职于两家知名的美元基金（富达亚洲风险投资与方源资本），主导了不同阶段的医疗行业投资，是医疗团队的核心成员之一。在此之前，钱晶女士是勃林格殷格翰（BI）中国区的副总裁，负责企业战略与业务发展，以及新产品规划两个部门。在此期间，钱晶女士领导了BI与Eli Lily的战略联盟，并主导了多个不同治疗领域的产品授权。钱晶女士的职业生涯开始于波士顿咨询（BCG），之后成为了麦肯锡中国与美国办公室的项目经理，专注于医疗健康领域。

钱晶女士于2004年取得美国宾夕法尼亚大学沃顿商学院MBA。

Dianna joined Pivotal China in 2018 as a Partner. Dianna has 20+ years of healthcare expertise; previously as core healthcare investment member at Fidelity Asia Growth Partners and FountainVest Partners. Prior to that, Dianna worked as Vice President at Boehringer Ingelheim China in charge of Business Development and New Product Planning, and Engagement Manager at McKinsey’s China and US offices specializing in healthcare sector.

Dianna graduated from Wharton Business School with an MBA degree in 2004.

早期创新合作经理/Manager,Early Innovation Partnering

强生创新/Johnson & Johnson Innovation

作为强生亚太创新的早期创新合作经理，王浩洵的主要职责是在亚太地区制定合作策略、积极寻找高潜力的早期合作研发项目并与新兴的抗感染领域和技术平台公司、企业家、风险投资机构和学术研究机构建立策略合作，以加速区域内创新。浩洵在美国新泽西罗格斯大学获得药学博士学位。

Haoxun Wang is the Early Innovation Partnering Manager at Johnson & Johnson Innovation, Asia Pacific. In this role, Haoxun is responsible for identifying strategic collaboration opportunities and building scientific connectivities with the emerging Infectious Diseases & Vaccines and Platform companies, entrepreneurs, venture capital groups, academic and research institutes across Asia Pacific. Haoxun holds a Ph.D. in Pharmaceutical Sciences from Rutgers University.

BD副经理/BD Associate Manager

信达生物/Innovent Biologics

2017年2日加入信达，目前主要负责国内BD，主导完成了葆元、劲方、来凯，参与和支持了赛诺菲、礼来、罗氏、亚盛、Coherus、MD Anderson、Etana合作交易。

Joined Innovent in Feb, 2017, and is currently responsible for China BD, and has led recent Innovent transactions with AnHeart, GenFleet, and Laekna, and has also supported the SVP of Business Development for in establishing several of Innovent’s existing partnerships with Sanofi, Lilly, Roche, Ascentage, Coherus, MD Anderson, Etana etc.

商务拓展副总裁/Vice President, Business Development

泽璟制药/Zelgen Biopharmaceuticals

首席投资官（大中华区）/CIO (Greater China)

康哲药业/CMS

华东理工大学化学工程学士；美国雪城大学化学工程博士。现担任康哲药业首席投资官（大中华区），负责集团战略投资和合作业务的拓展、新投资平台建设以及战略规划与实践。

曾任职于美国Cell   Genesys、AlphaVax及沈阳三生制药等多家国内外生物医药企业，从事工艺开发、研发管理和业务拓展工作；后任职于中诺创投、健壹资本和洪泰基金等专业医疗投资机构，专注于创新药物与医疗器械的风险投资。

Dr. Fei Jiang is the Chief Investment Officer (Greater China) of CMS   Group (0867.HK). He’s in charge of CMS’ strategic investment as well as   business development in Greater China Region.

Dr. Jiang got his Ph.D. degree in chemical engineering from Syracuse   University, New York at 2006, after receiving his bachelor degree, also in   chemical engineering, from East China University of Science and Technology,   Shanghai at 1998.

After graduation, he joined Cell Genesys at South San Francisco,   California, to develop cancer cell-based immunotherapy products, and AlphaVax   Inc. at Research Triangle Park, North Carolina, to develop RSV and CMV   vaccines.

Dr. Jiang returned to China and joined in 3SBio (1530.HK) at 2010. He   served as R&D Manager, and later R&D Director till 2013. He shifted   his role to BD Director since 2013, and took care of business development and   strategic alliance management for 3SBio. He joined in healthcare investment   business since 2017, and served as the Executive Director of Guijing Capital   and Sinopharm Capital, and the Managing Director of Aplus Capital   successively.

管理咨询业务大中华区负责人/Consulting Services Leader

科睿唯安/Clarivate Analytics

江雪博士现任科睿唯安（Clarivate）大中华区管理咨询业务（含生命科学与医疗健康）负责人。

他有超过13年生命科学与医疗健康领域行业经验，包括10年多的管理咨询和行业分析经验，以及2年工业研发和技术转移上的经验。

加入科睿唯安之前，江雪博士曾就职于药明康德上海总部，负责建立差异化的行业分析和咨询能力。他也曾就职于欧睿国际北美分部，为《财富》500强企业、领先新创公司、政府部门和投资机构等客户提供管理咨询和行业研究服务，并接受过美联社、Financial Post和CTV News等媒体采访，阐释行业观点。

他拥有美国Rutgers罗格斯大学（与UMDNJ新泽西医科和牙科大学联合项目）生物医学工程博士学位、上海交通大学学士学位（Top5%）以及多项发明专利。他还致力于消除贫困、科技普及和战胜疾病等方面的公益和慈善事业。

Dr. Xue Jiang is the Consulting Service Leader (including Life   Sciences and Healthcare) of Greater China at Clarivate Consulting.

He has 13+ years of industry experience in the life sciences and   healthcare sector, including more than 10 years of experience in management   consulting and industry analysis, and 2 years in industrial R&D and   technology transfer.

Prior to joining Clarivate, Dr. Jiang worked at WuXi AppTec   headquarters in Shanghai, where he was responsible for building   differentiated industry analysis and consulting capabilities. He has also   worked for Euromonitor International in North America, where he has provided   management consulting and industry research services to Fortune 500   companies, leading startups, government agencies and investment firms, and   has been interviewed by media outlets such as the Associated Press, Financial   Post and CTV News to share industry insight and perspectives.

He holds a Ph.D. in biomedical engineering from Rutgers University (a joint program with UMDNJ, University of Medical & Dental of New Jersey), a bachelor's degree from Shanghai Jiao Tong University (Top5%), and several utility patents. He is also committed to public welfare and philanthropic causes such as poverty eradication, promotion of science & technology, and the fight against disease.

高级副总裁及首席商务官/SVP and CCO

药明巨诺/JW Therapeutics

吴琼，现任药明巨诺首席商务官、高级副总裁，推动公司首个CAR-T产品倍诺达®从上市到商业化的迅速转型。扎根医疗行业28年，具有丰富的多产品线商业运营、战略规划及管理经验。吴琼曾是默沙东副总裁兼专科业务董事总经理，领导了多个产品领跑全球市场。他还曾先后在百特、西安杨森等跨国医疗公司担任要职，进行业务模式创新, 取得了卓越的商业化成果。吴琼拥有中欧国际工商学院高级管理人员工商管理硕士（EMBA）学位。

Alex Wu, Chief Commercial Officer (CCO) and Senior Vice President (SVP)  of JW Therapeutics, has accelerated first product commercialization. Alex has 28 years’ experience in portfolio commercial operation, strategy planning and management in healthcare industry. Before joining JW Therapeutics, Alex was Vice President and Managing Director of Hospital Specialty Business in MSD China, during which he has led plenty of products overriding global market. Prior to that, he also served with key position in Baxter, J&J and other MNCs. He created innovative commercial model and achieved outstanding outcome. Alex has obtained his EMBA (Executive Master of Business Administration) degree from China Europe International Business School (CEIBS).

资深副总裁/Senior Vice President

和黄医药/HUTCHMED

王清梅博士负责领导和黄医药的商务开发及战略合作。她深度参与和黄医药和所有合作伙伴（包括阿斯利康，雀巢健康科学及礼来公司）的互动与协商，在积极联络和推动执行方面发挥了关键作用。

王博士于2010年加入和记黄埔医药。此前，她任职美国礼来制药公司，负责礼来在中国及亚洲的生物研发。在礼来工作的16年间，领导过数个在传染病、炎症及抗肿瘤等领域的研发团队，共同发明了多个候选药物，包括2011年上市的丙肝创新药INCIVEK™（telaprevir, LY570310）。王博士著有50余篇文章，拥有多项国际专利，并担任过数个专刊和国际基金会的评委。王博士获得美国普渡大学的生物学博士学位。

Dr. Wang heads all alliance management and   business development for the company. She has been instrumental in engaging   with, negotiating, executing and very actively liaising with all our   development partners, including AstraZeneca, Nestlé Health Science, and Eli   Lilly.

Prior to joining HMP in 2010, Dr. Wang spent   16 years with Eli Lilly and was the Head for Asian Biology Research,   responsible for establishing and managing research collaborations in China   and Pan-Asia. Dr. Wang has broad drug discovery and development experience   spanning several therapeutic areas including infectious diseases,   inflammation and oncology. She was a co-inventor for several drug candidates   including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in   2011 for treatment of HCV infection.

Dr. Wang has numerous patents, published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.

中国区业务拓展负责人/Head of Business Development, China

科济药业/CARsgen Therapeutics

臧鹏博士， 科济药业中国区业务拓展负责人兼首席执行助理。负责中国区研发及商业化业务合作的拓展及支持科济药业全球业务拓展工作；负责科济药业产品管线的规划及管理。臧鹏拥有10余年的医药行业医学、市场、产品管线战略规划经验。加入科济药业之前，臧鹏担任上海罗氏制药有限公司的血液及早期新产品领域战略规划负责人，并在葛兰素史克、百时美施贵宝等公司有多年研发、医学及市场管理经验。

Dr Peng Zang, Head of Business Development, China and the Chief Executive Assistant to Chairman. Dr Zang is leads the business development activities of CARsgen in China, support the global BD activities, and leads the portfolio planning and management in CARsgen. Dr Zang has more than 10 years professional experiences of medical, marketing, and portfolio strategic planning in pharmaceutical industry. Prior to joining in CARsgen, he served as Strategic Planning Lead for Hematology and Early Assets in Roche China. Dr Zang has also taken multiple R&D and commercial roles in big multi-national pharmaceutical companies, including GSK and BMS.

创始人，董事长和首席执行官 /Founder, Chairman, and CEO

英诺湖医药/Innolake Biopharm

夏明德博士是英诺湖医药创始人，董事长和首席执行官，美中-药协（SAPA）董事（原总会会长）。夏博士在创立英诺湖医药公司前，在强生集团工作21年，是全球外部创新资深总监，受到过很多嘉奖，具有丰富的新药研发经验(包括临床前至临床阶段)，高超的投资孵化和商务运作能力。致力于推动国际项目合作, 资本投资和产业孵化，成功领导了超过50项强生外部合作项目。在此之前他曾在中国药科大学和耶鲁大学工作。美国化学学会的化学与工程新闻杂志曾对夏博士的有关科研成果进行了特别报道，作为科技领域的突破性进展。夏博士发表过超过60篇重量级文章和专利, 在哈佛大学商学院接受过培训，并担任中国科学院客座教授，几种世界一级杂志的审稿人，以及众多知名创新创业大赛的评委，作为大会主席，组织并主持了许多国际学术研讨会，促进了中国生物医药行业的对外交流及MAH政策的制定。夏博士创立的英诺湖医药聚焦于肿瘤和免疫疾病领域的创新药的研发，致力开发全球第一或者同类最优的药物，以满足中国和全球患者的迫切医疗需求。公司已组建了一支在新药研发和临床研究方面拥有丰富经验的海内外专家管理团队和建立了非常有差异化竞争优势的产品研发管线。同时借助内外部平台及优势资源，通过自主研发和全球合作等多元化模式，持续加强产品研发管线建设和推进产品开发上市进程。

Dr. Mingde Xia is the Founder, Chairman, and CEO of Innolake Biopharm. Prior to that, he was Senior Director of WWDA, Johnson & Johnson Global External Innovation, focusing on business partnership through investment, incubation, co-development, license and other collaboration vehicles. He worked with Johnson & Johnson for 21 years after career track at China Pharmaceutical University and Yale University, and successfully led / executed over 50 projects external collaboration for Johnson & Johnson three sectors (Pharm / Medical Device / Consumer). He is a guest / adjunct professor at the Chinese Academy of Sciences, a major inventor / author of over 60 patents / publications, a reviewer for a number of top quality international scientific journals, and an invited speaker for many international pharmaceutical conferences / forums. He received awards from American Chemical Society, Johnson & Johnson and different universities. He has actively involved in Sino-American Pharmaceutical Professionals Association (SAPA President 2008, Board of Directors 2008-present) and organized many international conferences in USA and Asia. Innolake Biopharm was registered in Hangzhou, China in 2020 with operations in Shanghai, Hangzhou, Suzhou China and NJ USA to develop transformative medicines for oncology and immunology diseases that address unmet medical needs with over $40 mln Pre-A Round funding. Senior management team have MNC and biopharma background with extensive experience in drug discovery, clinical trial and business development.

副总裁/Vice President

礼来亚洲基金/Lilly Asia Ventures

金家齐博士2019年加入礼来亚洲基金，目前担任投资副总裁。在此之前金博士于BCG波士顿咨询（上海办公室）任医疗健康领域相关资深咨询顾问。他于美国耶鲁大学取得遗传学专业博士学位，于复旦大学获得生物技术专业学士学位。

Dr. Jiaqi Jin joined Lilly Asia Fund in 2019 and currently serves as Vice President of Investments. Prior to that, Dr. Jin worked at BCG Boston Consulting (Shanghai office) as a senior consultant related to healthcare. He received his Ph.D. in genetics from Yale University and his B.S. in biotechnology from Fudan University.

CEO

西比曼/CBMG

刘必佐（Tony Liu）先生，CBMG创始人、董事长,兼首席执行官。八年来，他深耕生物医药领域，引领CBMG成为细胞治疗行业领军企业。CBMG拥有包括液体肿瘤、实体肿瘤和再生医学在内的广泛管线。根据已公布的数据，公司最前沿的C-CAR039 (CD19/CD20)双靶点CAR-T先进疗法具有成为同类最优产品的潜力。在实体瘤方面，CBMG不仅涵盖了深度创新的自主研发管线，同时还与全球大型制药企业针对国际尖端细胞治疗技术进行共同探索。CBMG还拥有多条成熟的干细胞管线，包括国内最先进入II 期临床试验的治疗膝骨关节炎 (KOA) 的“现货”同种异体 haMPC 疗法AlloJoin®。自主研发，合作共赢是CBMG不变的发展理念，过去几年，公司先后和诺华集团、阿斯利康等国际巨头达成战略合作。                                                          刘必佐先生曾任阿里巴巴（Alibaba）副总裁，负责阿里巴巴的海外战略投资，阿里巴巴旗下云计算万网（HiChina）CFO，以及海外电商平台“速卖通”总经理，全面负责集团国际电商平台的开发和推广。                                                                                  在2009年加入阿里巴巴集团之前，刘先生拥有美国微软公司（Microsoft）19年的工作经验，曾担任微软战略总经理，负责微软在中国的投资战略和企业战略规划，微软中国CFO，以及微软全球财务总监等职。

Mr. Liu formerly served as the Corporate Vice President at Alibaba Group responsible for Alibaba’s overseas investments. Since joining Alibaba in 2009, Tony held various positions including Corporate Vice President at B2B corporate investment, corporate finance, and General Manager for the B2C global e-commerce platform. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba, a leading internet infrastructure service provider. Prior to joining Alibaba, Tony spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. He was the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process. Tony was a key leader in the Microsoft corporate finance department during the 1990s as the Corporate Accounting Director. He was well recognized within Microsoft for driving an efficient worldwide finance consolidation, reporting, internal management accounting policy process, and showcased Microsoft’s best practices to many Fortune 500 companies in the U.S. Mr. Liu obtained his Washington State CPA certificate in 1992. He had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013 and was appointed as Chief Financial Officer in January 2014. He was appointed as Chief Executive Officer of the Company in February 2016.

首席运营官/COO

诺诚健华/Innocare

Kevin在生物医药等行业拥有超过25年的项目管理、工厂及公司运营管理经验。在诺诚健华，Kevin带领生产、采购、信息技术 (IT)、设备设施、供应链、工程建设管理等团队，打造更高效的运营管理平台，以支持公司的快速发展。在加入诺诚健华之前，Kevin担任百特公司亚太区供应链及生产运营副总裁。在为百特公司服务的近20年时间里，连续多年在高品质完成生产交付、质量与成本控制、工厂新建与产品技术转移，打造高效团队，以及政府与公共事务等方面取得优异成绩，在公司运营方面拥有扎实而丰富的经验。在此之前，Kevin在P&G公司服务6年主要专注于生产管理与项目管理。

Kevin从浙江大学获得机电一体化专业学士学位，并拥有中欧国际工商管理学院EMBA学位和比利时联合商学院DBA学位。

     Kevin has more than 25 years of manufacturing, supply chain and corporate operation management experiences in the pharmaceutical and biochemical industry. Kevin is primarily responsible for leading the Management functions and Guangzhou Subsidiary to build more efficient operation platforms to support the rapid growth and development of the Company at Innocare. 

Before join in the Innocare, Kevin served as Vice President responsible for the Supply Chain and Operation Management at Baxter，he has extensive experiences in manufacturing、quality and cost control、construction and government engagement. Beforehand, Kevin is focus on the manufacturing management and project management at P&G for 6 years.

Kevin received his bachelor’s degree in Mechanical & Electric from Zhejiang University, and obtained his the EMBA degree from China Europe International Business School (CEIBS) and PhD degree in Business Administration from United Business Institutes.

全球战略与项目管理部总经理/GM of GS&PMO

复宏汉霖/Henlius

盛严慈先生在复宏汉霖负责领导整个公司的战略制定工作，包括研发战略制定，产品管线管理，生产与供应链战略计划制定，商业化战略管理，以及项目管理等。

在进入复宏汉霖之前，盛严慈先生曾服务于葛兰素史克，罗氏制药，罗氏诊断，默沙东，海正辉瑞与致盛咨询。

盛严慈先生在业务战略，医学事务，处方药零售与广阔市场，商业渠道与市场准入，大客户管理，业务拓展（BD）与体外诊断领域都有非常丰富的工作经验。

Mr. Sheng is responsible for leading Henlius' strategy development, including R&D strategy, product pipeline, manufacture and supply chain, commercialization strategy and project management.

Before entering Henlius, Mr. Sheng worked for GSK, Roche Pharmaceuticals, Roche Diagnostics, Merck, Hisun Pfizer and Zhisheng Consulting.

Mr. Sheng has extensive experience in business strategy, medical affairs, prescription drug retail and broad market, commercial channels and market access, key account management, business development and in vitro diagnostics.

首席商业官/ Chief Commercial Officer

极目生物/Arctic Vision

陈轶先生拥有21年的眼科产品销售和市场营销经验。在加入极目生物之前，他负责艾尔建中国的眼保健业务，负责10多种产品（Ozurdex，Ganfort，Lumigan，Combigan，Refresh Tears等）的全部盈亏，涵盖四个不同的治疗领域（视网膜 /青光眼/ 激素类/人工泪液）。此前，他曾担任爱尔康的全国销售经理，领导多个产品的销售。在他职业生涯的早期，陈轶曾在MSD和勃林格殷格翰任职，在销售、市场、分销商管理方面具有丰富经验。

陈轶先生毕业于上海交通大学并获得口腔医学学士学位，并获得中欧国际工商学院（CEIBS）EMBA学位。

York Chen brings 21 years sales and marketing experience focusing in ophthalmic products. Before joining Arctic Vision, he headed Allergan China’s eye care business with full profit & loss responsibility of more than 10 products (Ozurdex, Ganfort, Lumigan, Combigan, Refresh Tears, etc.), covering four different treatment area (Retina/Glaucoma/Stac/Tears). Previously, he was the National Sales Manager at Alcon, leading the sales for multiple projects. Earlier in his career, York served at MSD and Boehringer Ingelheim with extensive experience in management of sales, marketing, distributors, private hospitals, and key accounts. York graduated from Shanghai JiaoTong university with a bachelor's degree in stomatology and obtained his EMBA from China Europe International Business School (CEIBS).

创始人、董事长、总经理/ Founder, Chairman & CEO

领诺医药/LINNO

1991年获武汉大学病毒学学士，1997年获军事医学科学院医学遗传学博士。2002年在美国国立卫生研究院（NIH）肿瘤研究所（NCI）完成药物发现研究方向博士后训练后，加入能源部Argonne国家实验室（ANL）参与功能基因组研究计划。2004年加入Vanderbilt University医学院任终身助理教授，在NIH基金资助下从事肿瘤生物学的基础与转化医学研究。2013年加入Alexion医药公司，开发双特异抗体研发平台，参与Strensiq®的BLA申请（2015年获EMA、FDA批准）并领导多个针对严重罕见病特别是靶向补体异常活化的治疗性项目的立项、实施和对外交流，有多个项目进入临床开发阶段。2017年底回国负责睿智化学（ChemPartner）抗体发现与工程改造技术平台，2019年8月在浦东张江药谷注册成立领诺医药。

Jack received a Bachelor’s degree of Science with a major in molecular biology and virology from Wuhan University in 1991. Upon his work on antibody and peptide discovery by using phage display technology, he was awarded MS and PhD degrees in medical genetics in 1994 and 1997, respectively, both from Chinese Academy of Medical Sciences. After finishing postdoctoral training in the Laboratory of Drug Discovery Research and Development, NCI-Frederick, he started as a staff scientist in Bioscience Division of Argonne National Laboratories (Chicago, IL) to work on high-throughput screening and generation of affinity reagents for functional and structural studies of intracellular and transmembrane proteins. Jack established and maintained a cancer research lab in school of medicine, Vanderbilt University since the fall of 2004, where his lab explored in vivo phage display technology for molecular imaging and tumor-targeted drug delivery, as well as novel target discovery.

Jack joined Alexion Pharmaceuticals Inc. in 2013 to establish capabilities of bi-specific antibody engineering, and develop next-generation therapeutics targeting complement proteins and other novel targets for treatment of ultra-rare devastating diseases with significant unmet medical needs. In the fall of 2017, Jack returned to Shanghai to lead the Antibody Discovery and Engineering Division of ChemPartner, a 3000-employee contracted research organization providing drug discovery services for multinational giant pharma, emerging biotech startups and academic investigators. Jack started Linno Pharmaceuticals Inc. at Zhangjiang High-tech Park in August of 2019.

亚太区外部创新和对外合作负责人/Head of External Innovation, Asia Pacific

诺和诺德/Novo Nordisk

Dr. Jenny Yang,  Head of Novo Nordisk External Innovation Asia Pacific, is fully responsible for identification, evaluation, and collaboration of enabling technologies, new targets, and novel therapeutics from idea to various clinical stages. Jenny graduated from Peking University. After obtaining her PhD degree from Columbia University, she did her postdoc training at California Institute of Technology and Howard Hughes Medical Institute. Jenny joined Novo Nordisk in 2008. She was Vice President of the company and leading drug discovery technology unit before taking her current role in Corporate Development in 2020. Jenny drives strategic planning, process establishment, program upgrade and execution of Novo Nordisk external innovation in Asia Pacific , aiming to nurture an open and innovative ecosystem in new drug discovery and development in China and Asia Pacific.

Jenny Yang博士， 诺和诺德亚太区外部创新和对外合作负责人， 专注于亚太区早期研究到临床各阶段新靶点、新项目和新技术的发现、评估、合作及引进。Jenny 毕业于北京大学， 在哥伦比亚大学获得博士学位后， 进入加州理工大学和霍华德休斯医学研究所从事博士后工作， 2008年加入诺和诺德，在2020年开始全面负责亚太区研发外部合作前， Jenny担任公司新药发现技术副总裁。Jenny通过领导外部创新和对外合作的战略规划，流程建设， 项目升级和行动实施， 积极推动中国和亚太区新药研发和开放创新生态的发展。

联合创始人，首席执行官，董事长/Founder, CEO and Board Chair

以明生物/Immune-Onc

廖晓伶博士毕业于北京大学生物系本科；保送北大研究生院；通过CUSBEA（中美分子生物学生物化学联合招生）选拔赴美到布兰戴斯大学获哲学博士学位， 师从2017 年诺贝尔奖得主Michael Rosbash；后进入加州大学旧金山分校进行博士后研究。2013 年5 月获美国斯坦福商学院高管培训。

廖晓伶博士2002 年起任美国基因泰克Genentech Inc. 药物开发高级项目领导， 成功领导多种创新药物的临床研发， 包括小分子和 大分子药品， 也包括癌症，免疫，代谢，神经，病毒及其他多种疾病的药物开发。基因泰克自2009 年为瑞士跨国公司罗氏并购。廖晓伶在2011 和2012 分别代表罗氏和基因泰克接待中国驻旧金山总领事馆，中国国家科技部，卫生部和药监部的访问并介绍创新经验。

廖晓伶于2016 年5 月离开基因泰克， 在硅谷组建创新生物医药公司 Immune-Onc Therapeutics,Inc. 并担任总裁，首席执行官和董事长。她目前是北京大学生命科学院尊师基金理事会成员， 以及华人生物学家协会 (CBIS) 理事会成员。

Charlene has 25 years of industry experience in drug development and businessleadership. From 2002-2016, Charlene held global drug development roles atGenentech where she was instrumental in leading development efforts across theproduct lifecycle for ten new molecular entities (NMEs) in a variety of therapeuticareas including: hematology-oncology, oncology, immunology, infectious diseases,and metabolic disorders. Prior to joining Genentech, Charlene was a Director of Business Development at Rigel. She began her career in biotech as a scientist atTularik, before its acquisition by Amgen.

Charlene holds a B.S. in Biochemistry from Peking University in China, andreceived her Ph.D. from Brandeis University in the laboratory of famed biologist.Dr. Michael Rosbash, who was awarded the 2017 Nobel Prize in Physiology orMedicine. Charlene completed her postdoctoral research in immunology at UCSF.

首席战略官兼中国区商务拓展负责人/Chief Strategy Officer & China BD head

博奥信/Biosion

叶信良博士是博奥信的首席战略官兼中国区商务拓展负责人，在制药行业有超过15年企业战略、资本市场及商务拓展等方面的广泛经验。

(Dr. Anthony Yeh is Chief Strategy Officer and Head of China business development (BD) of Biosion. He has over 15 years of broad pharmaceutical industry experience in strategy, capital market and business development.)

加入博奥信之前，叶博士曾任基石药业副总裁，负责企业战略、资本市场与投资者关系等工作。在基石的三年半期间，叶博士从助力公司上市，到成功推动创新药商业化上市的进程中，都扮演着关键的角色。在基石药业之前，叶博士还曾任雅培商业经济与战略部北亚区负责人及艾意凯咨询项目经理，专注于生命科学行业的战略制定、商务尽调及兼并收购。

(Before Biosion, Dr. Yeh was Vice President, Head of Corporate Strategy and Capital Market at CStone Pharmaceuticals. During his 3+ years at CStone, Dr. Yeh served different leadership roles in helping to build CStone through IPO and eventually to commercialization.Before CStone, Dr. Yeh was Regional Head of Business Economics and Strategy at Abbott.Before Abbott, Dr. Yeh was engagement manager at L.E.K. Consulting where he specialized in life sciences strategy, commercial due diligence, and M&A.)

叶博士拥有英国牛津大学的分子医学博士学位和澳大利亚昆士兰科技大学的生命科学荣誉学士学位。

(Dr. Yeh holds a Ph.D. in Molecular Medicine from University of Oxford and a Bachelor of Science (honors) from Queensland University of Technology.)

首席医学官/CMO

劲方医药/GenFleet Therapeutics

汪裕博士1995年毕业于同济医科大学（武汉）临床医学系。1995-2000年，在上海医科大学（现复旦大学医学院）研究生院外科学系攻读博士学位 (附属中山医院普外科胆道外科)。2000年7月毕业后在华东医院外科短暂工作。2001年至2004年间，在美国密歇根州Wayne State University医学院Barbara 肿瘤研究所进行肿瘤治疗领域的博士后研究，在相关学术杂志发表多篇文章。2004年回国后，先后在三维生物，礼来制药，葛兰素和赛诺菲亚太研发中心担任肿瘤领域医学负责人从事肿瘤药物的临床开发。2013-2016年，在诺华生物医学研究院临床肿瘤转化医学部门作为全球早期临床项目和试验的负责人，进行肿瘤产品临床早期研究，领导了数个first-in-class肿瘤靶向产品在全球的临床研究。汪裕博士于2016年11月-2017年12月作为首席科学官就职于博纳西亚医药科技有限公司。2018年1月创立详妍咨询，曾兼任国内多个上市医药公司、生物技术公司及学术研究机构高级医学顾问、外聘专家，和誉生物首席医学官。2020年至今任劲方医药首席医学官。

Dr. Wang Yu graduated from the Department of Clinical Medicine, Tongji Medical University (Wuhan, China) in 1995, and from 1995 to 2000, he studied for his PhD in the Department of Surgery, Shanghai Medical University (now Fudan University School of Medicine) (Department of General Biliary Surgery, Zhongshan Hospital). From 2001 to 2004, he conducted postdoctoral research in the field of oncology at the Barbara Institute of Oncology, Wayne State University School of Medicine, Michigan, USA, and published several articles in relevant academic journals. From 2013 to 2016, he worked in the Clinical Oncology Translational Medicine Department of Novartis Institutes of Biomedical Research as the leader of global early-stage clinical programs and trials, conducting early-stage clinical research on oncology products and leading several first-in-class oncology targeting products in global clinical research. research. Dr. Wang Yu worked as Chief Scientific Officer at Bonacia Pharmaceutical Technology Ltd. from November 2016 to December 2017.